Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
06 juin 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...